Product Description:

• 
  

  DAKLINZA is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection.

  
  

How to use:

• 60 mg taken orally once daily with or without food in combination with sofosbuvir with or without ribavirin.


• Recommended treatment duration: 12 weeks.

Caution & Warnings:

• Risk of Hepatitis B Virus Reactivation


• Bradycardia When Coadministered with Sofosbuvir and Amiodarone

Side Effects:

• Headache, anemia, fatigue, and nausea

Ingredients:

• Daclatasvir 60Mg.